LENZ — LENZ Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1815776 ·
Last close
$4.59
Market Cap
$144.22M
52W High
$8.49
52W Low
$4.53
ADV30
898,145
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,901,000 | 825,000 | -44,135,000 | -41,488,000 | 272,535,000 | 24,772,000 | 26,043,000 |
| Dec 2025 | 1,588,000 | — | -38,463,000 | -35,896,000 | 305,876,000 | 25,179,000 | 21,537,000 |
| Sep 2025 | 12,500,000 | — | -18,887,000 | -16,700,000 | 210,704,000 | 25,399,000 | 16,777,000 |
| Jun 2025 | 5,000,000 | — | -16,857,000 | -14,912,000 | 217,332,000 | 37,608,000 | 10,967,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-86,703,000
Investing CF
$-61,396,000
Financing CF
$149,715,000
CapEx
$-735,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.60
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-268,629,000
Inventory
$3,498,000
Receivables
$343,000
ST Investments
$233,613,000
EBIT TTM
$-118,342,000
Pretax Income TTM
$-108,494,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$21,475,000
EBITDA
$-135,204,000
Free Cash Flow
$-71,252,624
Enterprise Value
$-72,386,792
Total Cash
$220,003,008
Total Debt
$569,000
Shares Out
31,420,343
Trailing EPS
$-4.13
Book Value
$6.98
ROE
-59.2%
ROA
-37.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,088,000 | -91,138,000 | -82,127,000 | 305,876,000 | 21,537,000 | — | -69,170,000 |
| Dec 2024 | 0 | -58,610,000 | -49,769,000 | 215,304,000 | 11,220,000 | — | -59,391,000 |
| Dec 2023 | 0 | -72,429,000 | -69,968,000 | 70,376,000 | 163,088,000 | — | -60,380,000 |
| Dec 2022 | 15,000,000 | -10,483,000 | -10,811,000 | 46,951,000 | 71,120,000 | — | -4,091,000 |
TTM Snapshot
Revenues TTM
$1,086,000
NetIncome TTM
$-29,095,000
OpCashFlow TTM
$0
Assets (Latest)
$215,304,000
Forward EPS
$-3.08
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $4.59 · call volume: 38 · put volume: 1,102Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | $147.79M | $0.61 | — |
| TNYA | Tenaya Therapeutics, Inc. | $151.29M | $0.67 | — |
| MOLN | MOLECULAR PARTNERS AG | $165.05M | $4.40 | — |
| VXRT | Vaxart, Inc. | $123.82M | $0.51 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $123.81M | $2.15 | — |
News headlines (Yahoo Finance, 1h cache)
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts
2026-08-15 01:12 · Yahoo
LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...
2026-08-12 05:02 · Yahoo
LENZ Therapeutics Q2 Earnings Call Highlights
2026-08-11 23:04 · Yahoo
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
2026-07-22 14:00 · Yahoo
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
2026-07-06 12:15 · Yahoo
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
2026-06-24 12:30 · Yahoo
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
2026-06-08 15:33 · Yahoo
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
2026-06-07 23:30 · Yahoo
LENZ Therapeutics to Participate in Upcoming Investor Conferences
2026-05-26 12:00 · Yahoo
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade
2026-05-16 14:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.